| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036892589 |
| P356 | DOI | 10.2165/00002018-200528020-00006 |
| P698 | PubMed publication ID | 15691225 |
| P2093 | author name string | Dirk R J Kuypers | |
| P2860 | cites work | Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen | Q28141785 |
| Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells | Q28191714 | ||
| Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery | Q28206536 | ||
| Drug points: Premature osteonecrosis and sirolimus treatment in renal transplantation | Q28359700 | ||
| Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR | Q28361576 | ||
| Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 | ||
| Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes | Q28376025 | ||
| Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility | Q30835829 | ||
| Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience | Q31526307 | ||
| Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression | Q31832634 | ||
| Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production | Q31908887 | ||
| A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts | Q32048820 | ||
| Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity | Q33332141 | ||
| Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients | Q33332340 | ||
| Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations | Q33332540 | ||
| Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management | Q33332820 | ||
| Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated | Q33335178 | ||
| A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function | Q33335493 | ||
| Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels | Q70775037 | ||
| Case report--sirolimus rescue therapy for refractory renal allograft rejection | Q71062331 | ||
| Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model | Q71463351 | ||
| Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro | Q71508769 | ||
| Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation | Q71669568 | ||
| Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats | Q71700461 | ||
| Renal effects of rapamycin in the spontaneously hypertensive rat | Q72412671 | ||
| Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin | Q72537971 | ||
| Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit | Q72580987 | ||
| The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies | Q72628798 | ||
| Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats | Q72872991 | ||
| Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs | Q72887619 | ||
| Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates | Q73028842 | ||
| Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression | Q73044372 | ||
| Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group | Q73253906 | ||
| Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia | Q73337974 | ||
| Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration | Q73349035 | ||
| Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative | Q73378576 | ||
| Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients | Q73456717 | ||
| The trouble with kidneys derived from the non heart-beating donor: a single center 10-year experience | Q73648791 | ||
| Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat | Q73832072 | ||
| Living-donor kidney transplantation at Mayo Clinic--Rochester | Q73935835 | ||
| Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients | Q74121152 | ||
| Pediatric utilization of rapamycin for severe cardiac allograft rejection | Q74191605 | ||
| Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions | Q74477319 | ||
| Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients | Q77484646 | ||
| Hypertriglyceridemia in renal transplant recipients treated with sirolimus | Q77724864 | ||
| Predictors of renal transplant histology at three months | Q77793963 | ||
| Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model | Q77960609 | ||
| Sirolimus rescue therapy for refractory rejection in renal transplantation | Q95721512 | ||
| Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model | Q44064646 | ||
| Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange | Q44079044 | ||
| Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy | Q44082739 | ||
| Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. | Q44102328 | ||
| Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. | Q44106407 | ||
| Sirolimus-induced leukocytoclastic vasculitis | Q44157210 | ||
| Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients | Q44168474 | ||
| New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. | Q44200460 | ||
| Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine | Q44221070 | ||
| Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy | Q44233380 | ||
| Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients | Q44236018 | ||
| Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors | Q44256933 | ||
| Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation | Q44256950 | ||
| Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients | Q44261905 | ||
| Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem? | Q44288747 | ||
| Bone mineral density changes within six months of renal transplantation | Q44289403 | ||
| Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients | Q44289430 | ||
| Early experience with sirolimus in lung transplant recipients with chronic allograft rejection | Q44312072 | ||
| Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. | Q44313379 | ||
| Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies | Q44321472 | ||
| Diabetes mellitus after kidney transplantation in the United States | Q44326129 | ||
| Sirolimus may promote thrombotic microangiopathy | Q44326132 | ||
| Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression. | Q44330635 | ||
| Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. | Q44378937 | ||
| The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy | Q44379119 | ||
| Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation | Q44402537 | ||
| Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. | Q44405395 | ||
| Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience | Q44437917 | ||
| Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience | Q44437921 | ||
| Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients—a single center experience | Q44437938 | ||
| Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients | Q44437948 | ||
| Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience | Q44437952 | ||
| Kidney transplantation without calcineurin inhibitors using sirolimus. | Q44437956 | ||
| Conversion to sirolimus in solid organ transplantation: a Single-Center experience | Q44437963 | ||
| Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a Single-Center experience | Q44437966 | ||
| Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation | Q44437975 | ||
| De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco | Q44437985 | ||
| Rapamycin: signaling in vascular smooth muscle | Q44437992 | ||
| Pneumonitis associated with the use of mycophenolate mofetil | Q44460475 | ||
| Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. | Q44461489 | ||
| Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation | Q44469215 | ||
| Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction | Q44471173 | ||
| Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients | Q44491034 | ||
| Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation | Q44491733 | ||
| A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients | Q44493612 | ||
| Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. | Q44493644 | ||
| Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient | Q44493997 | ||
| The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses | Q44508122 | ||
| Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). | Q44514934 | ||
| Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients | Q44527258 | ||
| Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis | Q44527275 | ||
| Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial | Q33338797 | ||
| Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure | Q33339056 | ||
| Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients | Q33339059 | ||
| De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination | Q33341564 | ||
| Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination | Q33345776 | ||
| Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? | Q33346767 | ||
| Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study | Q33347960 | ||
| Sirolimus: a single center experience in combination with calcineurin inhibitors. | Q33347963 | ||
| A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function | Q33348393 | ||
| Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study | Q33349178 | ||
| De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus | Q33349848 | ||
| Thrombotic microangiopathy after renal transplantation in the United States | Q33357327 | ||
| Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal | Q33359653 | ||
| Enhancement of human platelet aggregation and secretion induced by rapamycin | Q33504794 | ||
| Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation | Q33925685 | ||
| Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus | Q33925690 | ||
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | Q33968031 | ||
| A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration | Q34129460 | ||
| Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation | Q34176754 | ||
| Effects of rapamycin on cultured hepatocyte proliferation and gene expression | Q34240244 | ||
| Sirolimus-associated pulmonary toxicity | Q34317056 | ||
| Clinical pharmacokinetics of sirolimus | Q34347243 | ||
| International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology | Q34354852 | ||
| Death with functioning graft--a preventable cause of graft loss. | Q34659898 | ||
| Rapamycin inhibits GM-CSF-induced neutrophil migration | Q34781893 | ||
| Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients | Q35053894 | ||
| Clinical epidemiology of cardiac disease in renal transplant recipients | Q35086955 | ||
| Pharmacokinetics of tacrolimus-based combination therapies | Q35124324 | ||
| A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection | Q35125083 | ||
| Sirolimus: its discovery, biological properties, and mechanism of action | Q35125746 | ||
| Therapeutic monitoring of sirolimus: its contribution to optimal prescription. | Q35125770 | ||
| Preclinical results of sirolimus treatment in transplant models | Q35125793 | ||
| Molecular actions of sirolimus: sirolimus and mTor | Q35125798 | ||
| Sirolimus-induced pneumonitis: three cases and a review of the literature | Q35608779 | ||
| Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients | Q35817128 | ||
| Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study | Q38525562 | ||
| Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation | Q39420730 | ||
| A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year | Q40535785 | ||
| Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses | Q40643579 | ||
| Rapamycin is an effective inhibitor of human renal cancer metastasis. | Q40664831 | ||
| The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand | Q40707638 | ||
| Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel | Q40743752 | ||
| Mechanism of action of the immunosuppressant rapamycin | Q40965429 | ||
| The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo | Q41447199 | ||
| Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria | Q41787336 | ||
| Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model | Q41886213 | ||
| The effect of rapamycin on kidney function in the Sprague-Dawley rat. | Q41923533 | ||
| A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients | Q42415027 | ||
| Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro | Q42475482 | ||
| Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. | Q42544482 | ||
| Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone | Q42550663 | ||
| Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. | Q42552889 | ||
| A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. | Q42598004 | ||
| Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. | Q42680562 | ||
| Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation | Q43453547 | ||
| Sirolimus improves the two-year outcome of renal allografts in African-American patients | Q43493492 | ||
| Immunosuppressant use without bone loss--implications for bone loss after transplantation | Q43517225 | ||
| Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation | Q43534748 | ||
| Effect of histological damage on long-term kidney transplant outcome | Q43547328 | ||
| Effect of rapamycin and FK506 on mesangial cell proliferation | Q43552846 | ||
| Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. | Q43584947 | ||
| Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus | Q43604915 | ||
| Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation | Q43633987 | ||
| Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients | Q43685021 | ||
| Sirolimus-associated eyelid edema in kidney transplant recipients | Q43685041 | ||
| Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation | Q43703063 | ||
| Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells | Q43735102 | ||
| Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications | Q43738218 | ||
| Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus | Q43747072 | ||
| Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? | Q43747084 | ||
| Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation | Q43752523 | ||
| Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). | Q43758772 | ||
| Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients | Q43768135 | ||
| Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity | Q43828472 | ||
| Are wound complications after a kidney transplant more common with modern immunosuppression? | Q43843799 | ||
| Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice | Q43949026 | ||
| The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials | Q44024985 | ||
| Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. | Q44033366 | ||
| European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients | Q44046247 | ||
| Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study | Q44527287 | ||
| Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients | Q44527309 | ||
| Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation | Q44549982 | ||
| Rapamycin in lung transplantation: preliminary results | Q44577658 | ||
| Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. | Q44583035 | ||
| Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study | Q44585215 | ||
| Rapamycin-induced oligospermia | Q44591465 | ||
| Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1 | Q44595688 | ||
| Human herpesvirus-6 in renal transplant recipients: potential risk factors for the development of human herpesvirus-6 seroconversion. | Q44608613 | ||
| Sirolimus-Induced Interstitial Pneumonitis in an Islet Transplant Recipient | Q44631791 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Testosterone concentrations and sirolimus in male renal transplant patients. | Q44695059 | ||
| The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients | Q44701667 | ||
| Sirolimus inhibits oxidative burst activity in transplant recipients. | Q44701677 | ||
| Sirolimus myopathy | Q44701679 | ||
| Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function | Q44705288 | ||
| Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury | Q44711152 | ||
| Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation | Q44728988 | ||
| A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year | Q44741819 | ||
| Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | Q44741825 | ||
| Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction | Q44771237 | ||
| Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1. | Q44799975 | ||
| Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma | Q44799991 | ||
| Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure | Q44845167 | ||
| Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity | Q44845957 | ||
| Lymphedema associated with sirolimus in renal transplant recipients. | Q44846974 | ||
| Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies | Q44854978 | ||
| Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation | Q44860714 | ||
| Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy | Q44866395 | ||
| Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination | Q44899011 | ||
| Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years | Q44899016 | ||
| Sirolimus-induced angioedema | Q44899034 | ||
| Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? | Q44906768 | ||
| Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice | Q44913829 | ||
| Sirolimus impairs gonadal function in heart transplant recipients | Q44935460 | ||
| Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil | Q44958299 | ||
| Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies | Q44963400 | ||
| Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus | Q44967971 | ||
| Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation | Q44989307 | ||
| Sirolimus-induced leukocytoclastic vasculitis: the second case reported | Q45016050 | ||
| Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction | Q45057604 | ||
| De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. | Q45100299 | ||
| Alterations of the female reproductive system in recipients of islet grafts | Q45183364 | ||
| Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. | Q46449145 | ||
| Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment | Q56907406 | ||
| Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study | Q57943257 | ||
| Sirolimus-tacrolimus combination immunosuppression | Q60998185 | ||
| Management of lymphoceles after kidney transplantation | Q62517980 | ||
| Functional and histopathologic effects of rapamycin on mouse kidney | Q70601660 | ||
| P433 | issue | 2 | |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 153-181 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Benefit-risk assessment of sirolimus in renal transplantation | |
| P478 | volume | 28 |
| Q39024541 | A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation |
| Q36003663 | Alleviating neurodegeneration in Drosophila models of PolyQ diseases |
| Q36769277 | Allogeneic hematopoietic stem-cell transplantation for sickle cell disease |
| Q36328854 | An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice |
| Q38038696 | An evaluation of sirolimus in renal transplantation |
| Q33253253 | Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants |
| Q37821472 | Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? |
| Q37517602 | Considerations in sirolimus use in the early and late post-transplant periods |
| Q36874564 | Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. |
| Q27320627 | Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease |
| Q39820135 | Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons |
| Q35706983 | Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial |
| Q57792492 | Everolimus and Enteric-Coated Mycophenolate Sodium Ab Initio after Liver Transplantation: Midterm Results |
| Q33394235 | Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial |
| Q36441466 | Everolimus: a review of its use in renal and cardiac transplantation |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q48097984 | Evidence of the immunomodulatory role of dual PI3K/mTOR inhibitors in transplantation: an experimental study in mice. |
| Q46449559 | Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure |
| Q27323092 | High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model |
| Q35827879 | Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity. |
| Q36938148 | Kidney transplantation: current issues and future prospects |
| Q51497219 | Kinetic nomograms assist individualization of drug regimens. |
| Q33513711 | Mechanisms of diabetes mellitus induced with FK506 in SD rats models |
| Q57817480 | Rapamycin Nano-Micelle Ophthalmic Solution Reduces Corneal Allograft Rejection by Potentiating Myeloid-Derived Suppressor Cells' Function |
| Q46755906 | Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis |
| Q83220038 | Side effects of sirolimus |
| Q34767143 | Sirolimus is associated with new-onset diabetes in kidney transplant recipients. |
| Q36936424 | Sirolimus-associated infertility: case report and literature review of possible mechanisms |
| Q36674174 | Sirolimus-associated proteinuria and renal dysfunction |
| Q33604754 | Surgical biology for the clinician: vascular effects of immunosuppression |
| Q46936587 | Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. |
| Q38946734 | The antiaging activity and cerebral protection of rapamycin at micro-doses. |
| Q35823680 | The food additive vanillic acid controls transgene expression in mammalian cells and mice |
| Q36652031 | The role and value of sirolimus administration in kidney and liver transplantation |
| Q41859603 | The use of everolimus in renal-transplant patients |
| Q33432698 | Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients |
| Q36985076 | Transporter-mediated uptake into cellular compartments |
| Q38161821 | What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy? |
| Q80051902 | [Sirolimus-induced onychopathy in renal transplant recipients] |
Search more.